Summary: - Charles River reported Q2 2020 results that beat the top and bottom line estimates. However, the company's research business contended with strong headwinds again this quarter. - The COVID-19-related headwinds will likely continue to impact Charles River's results in the near-term, but the company is still well-positioned for the future (the revised 2020 guidance proves it). - This small-cap drug discovery and early-stage development company has a great long-term s